Welcome to our dedicated page for Accuray Incorp news (Ticker: ARAY), a resource for investors and traders seeking the latest updates and insights on Accuray Incorp stock.
Accuray Incorporated (NASDAQ: ARAY) generates a steady flow of news related to radiation oncology, product innovation, clinical collaborations and corporate strategy. As a developer and manufacturer of radiation therapy systems such as the CyberKnife System and the Radixact Treatment Delivery System, the company regularly issues updates on technology launches, clinical milestones and organizational changes that are relevant to investors, clinicians and other stakeholders following ARAY stock.
News about Accuray often highlights advances in its radiation therapy portfolio. Recent announcements have included the introduction of the Accuray Stellar Solution, a configuration of the Radixact system initially for the U.S. market, designed to support adaptive radiotherapy and multiple delivery modalities. The company also reports on collaborations, such as a memorandum of understanding with the University of Wisconsin School of Medicine and Public Health to advance online adaptive radiotherapy on its helical radiation treatment delivery platform.
Corporate and financial developments are another key focus of Accuray’s news flow. Press releases and related SEC filings cover quarterly and annual financial results, guidance, non-GAAP measures such as adjusted EBITDA, and details of a comprehensive strategic, operational and organizational transformation plan. These communications describe initiatives such as streamlining the commercial structure, centralizing core functions, outsourcing selected non-core activities, and workforce reductions, along with associated restructuring charges and expected effects on operating profitability.
Governance and capital structure updates also appear in the company’s news. Examples include leadership changes, board appointments, equity incentive plans, and financing agreement amendments that involve warrants to purchase common stock. Clinical and market expansion stories, such as the first CyberKnife S7 System treatments in Melbourne, Australia through a collaboration with 5D Clinics and Icon Group, illustrate how Accuray’s technology is being deployed in new locations and settings.
This ARAY news page brings together these types of announcements in one place, allowing readers to review product launches, clinical collaborations, financial disclosures and transformation updates over time. For anyone researching Accuray’s business direction, technology focus or corporate actions, the news feed offers a structured view of the company’s public communications.
Accuray Incorporated (NASDAQ: ARAY) reported its fiscal Q2 2021 results, with net revenue of $97.5 million, slightly down from $98.8 million year-over-year. The company achieved gross orders of $75.4 million, increasing backlog by 11% to $596.2 million. GAAP net income was $4.8 million or $0.05 per share, a decline from $10.7 million in the prior year due to a non-cash gain. Adjusted EBITDA rose to $13.5 million from $7.1 million. The company did not provide fiscal 2021 guidance due to COVID-19 uncertainties.
Accuray Incorporated (NASDAQ: ARAY) announced promising results from a phase II trial involving 338 women with low-risk breast cancer. Seven years after receiving once-daily accelerated partial breast irradiation (APBI) with the TomoTherapy System, 98.8% achieved local disease control. The study, published in the International Journal of Radiation Oncology*Biology*Physics, found minimal acute and late toxicities. Key findings include 99.4% ipsilateral breast tumor recurrence-free control at 76 months and excellent patient-reported outcomes regarding breast appearance.
Accuray Incorporated (NASDAQ: ARAY) will announce its financial results for the second quarter of fiscal year 2021, ending December 31, 2020, on January 27, 2021, after market close. A conference call is scheduled for the same day at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. Investors can participate via dial-in or listen to a live webcast available on the Company's Investor Relations website. A replay of the call will also be accessible for one week following the event.
Accuray Incorporated (Nasdaq: ARAY) will participate in the 39th J.P. Morgan Annual Healthcare Conference on January 14, 2021, at 11:00 am Pacific / 2:00 pm Eastern. Josh Levine, President and CEO, is set to present. The presentation can be accessed on Accuray's official website post-event. Institutional investors are invited to arrange one-on-one virtual meetings with senior management during the conference. Accuray is dedicated to advancing radiation therapy solutions for complex medical cases.
Accuray Incorporated (NASDAQ: ARAY) has received 510(k) clearance from the FDA for its ClearRT™ Helical kVCT Imaging. Integrated with the Radixact® System, this advanced imaging solution enhances diagnostic quality, enabling faster patient setup and improved treatment accuracy. Scheduled for commercial release in Spring 2021, ClearRT offers superior image quality and versatility, providing essential support for radiation therapy. Accuray aims to meet the diverse needs of patients while maintaining a high standard of care with this innovative technology.
Accuray Incorporated (NASDAQ: ARAY) announced inducement awards for new Senior Vice President, Quality & Regulatory Affairs, Jim Dennison. Effective November 30, Dennison will receive 56,053 restricted stock units and a stock option for 105,485 shares at an exercise price of $4.46. The awards are not part of the current equity plan but follow guidelines similar to those in the 2016 Equity Incentive Plan. Restricted stock units will vest annually, while the stock option will vest 25% after one year and monthly thereafter, contingent on Dennison's ongoing service.
Accuray Incorporated (NASDAQ: ARAY) and DHL Supply Chain have formed a global service parts logistics partnership aimed at enhancing Accuray's supply chain and customer service capabilities. This collaboration, effective February 2021, will create a dedicated logistics network across 34 warehousing sites in 16 countries, ensuring medical teams have reliable access to critical radiotherapy technologies. DHL's Control Centers in Columbus, Budapest, and Singapore will provide 24/7 operational support, while advanced software tools will enhance inventory management.
Accuray has appointed Jim Dennison as senior vice president of global quality and regulatory affairs, effective immediately. Dennison, with nearly 15 years at GE Healthcare, will oversee quality, regulatory, and government affairs, reporting to Joshua H. Levine, CEO. His previous experience includes managing global design and manufacturing sites, standardizing quality systems, and improving FDA submission processes. Accuray expresses confidence in Dennison's ability to advance quality and regulatory functions to support R&D investments and market expansion.
Accuray Incorporated (NASDAQ: ARAY) showcased its latest innovations in radiation therapy at the ASTRO Annual Meeting on Nov 10, 2020. The company emphasized the enhanced capabilities of its CyberKnife and TomoTherapy platforms, particularly the Radixact System, designed for hypofractionated treatments. Notable advancements include the Synchrony Motion Synchronization technology, enabling real-time adaptive therapy, and the CyberKnife S7 System, ensuring precision in delivering treatments. The introduction of ClearRT Helical kVCT Imaging further enhances patient care through improved imaging capabilities.
Accuray Incorporated (NASDAQ: ARAY) reported its Q1 fiscal 2021 results, ending September 30, 2020, with net revenue of $85.3 million and operating income of $5.5 million. Adjusted EBITDA increased to $9 million from a loss of $1 million year-over-year. Gross orders were $50.5 million, and the backlog rose to $597.3 million, marking a 21% increase compared to the previous year. Notably, revenue from products decreased from $37.6 million to $31.3 million, while service revenue grew slightly to $54.1 million. The company refrained from providing fiscal 2021 guidance due to COVID-19 uncertainty.